Blueprint Medicines Balance Sheet Health
Financial Health criteria checks 4/6
Blueprint Medicines has a total shareholder equity of $310.7M and total debt of $507.2M, which brings its debt-to-equity ratio to 163.3%. Its total assets and total liabilities are $1.0B and $727.8M respectively.
Key information
163.3%
Debt to equity ratio
US$507.20m
Debt
| Interest coverage ratio | n/a |
| Cash | US$647.90m |
| Equity | US$310.69m |
| Total liabilities | US$727.79m |
| Total assets | US$1.04b |
Recent financial health updates
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?
Apr 26
Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?
Nov 20Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?
Jul 26Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?
Apr 16Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt
Dec 12Recent updates
Blueprint Medicines Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 05Blueprint Medicines: Rampant Growth Mostly Priced In
May 04Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?
Apr 26Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC)
Apr 05Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)
Feb 20Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate
Jan 08Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%
Dec 18Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?
Nov 20Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?
Jul 26Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?
Apr 16Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 09Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt
Dec 12Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates
Nov 07Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal
Sep 15Blueprint to seek label expansion for systemic mastocytosis therapy after trial win
Aug 17Blueprint Medicines reports Q2 earnings miss; reaffirms FY22 guidance
Aug 02Blueprint to sell Ayvakit royalty for $250M upfront; Gavreto royalty for $175M upfront
Jun 30Time To Worry? Analysts Just Downgraded Their Blueprint Medicines Corporation (NASDAQ:BPMC) Outlook
Feb 17Financial Position Analysis
Short Term Liabilities: BPMC's short term assets ($776.6M) exceed its short term liabilities ($206.6M).
Long Term Liabilities: BPMC's short term assets ($776.6M) exceed its long term liabilities ($521.2M).
Debt to Equity History and Analysis
Debt Level: BPMC has more cash than its total debt.
Reducing Debt: BPMC's debt to equity ratio has increased from 0% to 163.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BPMC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BPMC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.